Terms: = Prostate cancer AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED AND Prognosis
17 results:
1. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
[TBL] [Abstract] [Full Text] [Related]
2. The ELAVL3/mycn positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.
Ji Y; Zhang W; Shen K; Su R; Liu X; Ma Z; Liu B; Hu C; Xue Y; Xin Z; Yang Y; Li A; Jiang Z; Jing N; Zhu HH; Dong L; Zhu Y; Dong B; Pan J; Wang Q; Xue W
Nat Commun; 2023 Nov; 14(1):7794. PubMed ID: 38016952
[TBL] [Abstract] [Full Text] [Related]
3. A mycn-independent mechanism mediating secretome reprogramming and metastasis in
Zhang HF; Delaidelli A; Javed S; Turgu B; Morrison T; Hughes CS; Yang X; Pachva M; Lizardo MM; Singh G; Hoffmann J; Huang YZ; Patel K; Shraim R; Kung SHY; Morin GB; Aparicio S; Martinez D; Maris JM; Bosse KR; Williams KC; Sorensen PH
Sci Adv; 2023 Aug; 9(34):eadg6693. PubMed ID: 37611092
[No Abstract] [Full Text] [Related]
4. Development of VPC-70619, a Small-Molecule n-myc Inhibitor as a Potential Therapy for Neuroendocrine prostate cancer.
Ton AT; Foo J; Singh K; Lee J; Kalyta A; Morin H; Perez C; Ban F; Leblanc E; Lallous N; Cherkasov A
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269731
[TBL] [Abstract] [Full Text] [Related]
5. n-myc promotes angiogenesis and therapeutic resistance of prostate cancer by TEM8.
Li M; Fang L; Kwantwi LB; He G; Luo W; Yang L; Huang Y; Yin S; Cai Y; Ma W; Zhan H; Tong Z; Zhang L; Liang C; Yin Y
Med Oncol; 2021 Sep; 38(10):127. PubMed ID: 34523032
[TBL] [Abstract] [Full Text] [Related]
6. Activated ALK Cooperates with n-myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine prostate cancer.
Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
[TBL] [Abstract] [Full Text] [Related]
7. A modern era of personalized medicine in the diagnosis, prognosis, and treatment of prostate cancer.
Lakshmanan VK; Ojha S; Jung YD
Comput Biol Med; 2020 Nov; 126():104020. PubMed ID: 33039808
[TBL] [Abstract] [Full Text] [Related]
8. n-myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
[TBL] [Abstract] [Full Text] [Related]
9. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S; Inoue T; Ogawa O; Gleave ME
Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
[TBL] [Abstract] [Full Text] [Related]
10. Proteomic Characterization of prostate cancer to Distinguish Nonmetastasizing and Metastasizing Primary Tumors and Lymph Node Metastases.
Müller AK; Föll M; Heckelmann B; Kiefer S; Werner M; Schilling O; Biniossek ML; Jilg CA; Drendel V
Neoplasia; 2018 Feb; 20(2):140-151. PubMed ID: 29248718
[TBL] [Abstract] [Full Text] [Related]
11. Long noncoding RNAs and neuroblastoma.
Pandey GK; Kanduri C
Oncotarget; 2015 Jul; 6(21):18265-75. PubMed ID: 26087192
[TBL] [Abstract] [Full Text] [Related]
12. Molecular foundations for personalized therapy in prostate cancer.
Fisher KW; Montironi R; Lopez Beltran A; Moch H; Wang L; Scarpelli M; Williamson SR; Koch MO; Cheng L
Curr Drug Targets; 2015; 16(2):103-14. PubMed ID: 25547910
[TBL] [Abstract] [Full Text] [Related]
13. prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.
Park K; Chen Z; MacDonald TY; Siddiqui J; Ye H; Erbersdobler A; Shevchuk MM; Robinson BD; Sanda MG; Chinnaiyan AM; Beltran H; Rubin MA; Mosquera JM
Hum Pathol; 2014 Oct; 45(10):2136-43. PubMed ID: 25128228
[TBL] [Abstract] [Full Text] [Related]
14. Small cell carcinoma of the prostate.
Nadal R; Schweizer M; Kryvenko ON; Epstein JI; Eisenberger MA
Nat Rev Urol; 2014 Apr; 11(4):213-9. PubMed ID: 24535589
[TBL] [Abstract] [Full Text] [Related]
15. n-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin.
Song Y; Oda Y; Hori M; Kuroiwa K; Ono M; Hosoi F; Basaki Y; Tokunaga S; Kuwano M; Naito S; Tsuneyoshi M
Hum Pathol; 2010 Feb; 41(2):214-22. PubMed ID: 19800102
[TBL] [Abstract] [Full Text] [Related]
16. Role of the MRP1/ABCC1 multidrug transporter protein in cancer.
Munoz M; Henderson M; Haber M; Norris M
IUBMB Life; 2007 Dec; 59(12):752-7. PubMed ID: 18085475
[TBL] [Abstract] [Full Text] [Related]
17. Dickkopf-1 is down-regulated by mycn and inhibits neuroblastoma cell proliferation.
Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
[TBL] [Abstract] [Full Text] [Related]
